NUP98 11p15 Rearrangement
Expected Turnaround Time
5 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
FISH test on hematologic specimens for detection of NUP98 (11p15) gene rearrangement. NUP98 is known to fuse to at least 28 different partner genes in patients with hematopoietic malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML) in blast crisis, myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), and bilineage/biphenotypic leukemia.
Requisition Forms
Specimen Requirements
Specimen Requirements
- Whole Blood: 5 mL, EDTA preferred (NaHep accepted)
- Bone Marrow Aspirate: 3 mL, EDTA preferred (NaHep accepted)
Specimen Stability
72 hours
Storage Requirements
- Whole Blood: 2°C to 25°C
- Bone Marrow Aspirate: 2°C to 25°C
- Fixed Cytogenetically Prepared Cells: -28°C to -15°C
Shipping Conditions
Ambient, Refrigerated
Shipping Recommendations
AMBIENT, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen. Do not freeze.
Specimen Rejection Criteria
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells
Test Details
Keywords
Fluorescence in-situ Hybridization, Leukemia, Oncology, Oncology FISH Probes, Myeloid dysplastic syndrome (MDS), Myeloid
Test Method
Fluorescence in situ hybridization (FISH)
Methodology Category
FISH
Regulatory Status
ASR
Special Considerations
All attempts will be made to process and report samples received > 72 hours post-collection. Bone marrow is the sample of choice in most heme malignancies.
Associations
acute myeloid leukemia (AML), chronic myeloid leukemia (CML) in blast crisis, myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), and bilineage/biphenotypic leukemia